A Recent Study Says Self-Monitoring Blood Glucose Devices Market Will Make a Huge Impact in near Future | Top Players Abbott 88, Ascensia Diabetes Care Holdings AG. 91, Arkray, Inc. 96, All Medicus Co., Ltd. 100, Bayer Corporation. 102, B. Braun Melsungen

Proven to be a critical component in the diabetes management process, the self-monitoring blood glucose devices market has registered an impressive growth rate owing to the prevalence of diabetes worldwide and the availability of diverse monitoring solutions. According to reliable data, about 8.8 percent of the global adult population in 2017 had diabetes, and this number is estimated to crawl up to 9.9 percent by 2045. Considering the total number of diabetic patients this percentage amounts to, the self-monitoring blood glucose devices industry could cater to virtually millions of consumers over the coming years. Unrestricted fast-food consumption among the millennials supplemented by the rising disposable income could accelerate the prevailing issue of obesity, which greatly indicates the onset of diabetes. The global self-monitoring blood glucose devices market, amassing a remuneration of over USD 14.3 billion in 2017, will be further boosted by the rising geriatric population that commonly experiences difficulty in controlling sugar levels.
Self-Monitoring Blood Glucose Devices Market size was valued at USD 14.3 billion in 2017 and is expected to witness 5.1% CAGR from 2018 to 2024.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/2743

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
1. Abbott 88
2. Ascensia Diabetes Care Holdings AG. 91
3. Arkray, Inc. 96
4. All Medicus Co., Ltd. 100
5. Bayer Corporation. 102
6. B. Braun Melsungen Medical AG. 107
7. Bionime Corporation. 111
8. Dexcom Inc. 116
9. Essenlife Bioscience Inc 119
10. Eumed Biotechnology Ltd. 120

Although clinic tests offer a comprehensive understanding of blood glucose levels and make effective comparison with past data, these tests are only done a few times in a year by diabetic patients, whereas glucose levels actually fluctuate throughout the day. Awareness pertaining to the usefulness of data provided by daily blood tests and the motivating output given by them has expanded the self-monitoring blood glucose devices market penetration in the home care segment. Key factors that induce a sense of comfort for diabetic patients while using these devices include ease of handling, clear and bigger displays, accurate figures and ability to double check for ensuring correct measurement. Adherence to internationally recognized standards has also encouraged the acceptance of self-monitoring devices as part of everyday life. With greater access to advanced portable devices that meet the expectations of diabetic patients and the need for maintaining a healthy personal and work lifestyle, the self-monitoring blood glucose devices market from use in home settings will register a CAGR of 5.7% from 2018 to 2024.

Browse Report Summary @ https://www.gminsights.com/industry-analysis/self-monitoring-blood-glucose-devices-market

Initially, the segment was bursting with a slew of monitoring devices that required fine needle-pricks to get blood for testing, but the advent of continuous glucose monitors (CGM) help to develop less invasive methods to monitor glucose levels. In essence, CGMs are critical in discerning patterns in glucose level changes and assist in predicting the occurrence of low or high blood sugar levels in home as well as hospital patient, making them a significant part of the self-monitoring blood glucose devices industry. With sensors inserted under the skin to deliver real-time glucose level readings and charting out the changes to recognize glucose level triggers, CGMs offer a competent solution to allow for necessary adjustments required for improved living.

Innovative CGMs are constantly redefining the self-monitoring blood glucose devices market dynamics, such as Abbot’s novel flash glucose monitoring system. The American healthcare company’s FreeStyle Libre is a self-applied personal glucose sensor that diabetic patients can wear for up to 14 days at a time. The highly accurate device is approved by the FDA and is more affordable when compared to other CGM alternatives in the market. Using the sensor, which is worn on the backside of the upper arm, diabetics are able to read real-time data and identify trends in glucose fluctuation by studying eight hours of glucose level information.
With over 800,000 people in more than 43 countries using Abbot’s FreeStyle Libre, it is an example of the growing popularity of continuous glucose monitors, giving enormous propulsion to the self-monitoring blood glucose devices market. Along with Abbott Laboratories, Bayer Healthcare, All Medicus, Dexcom, Arkray, Bionime Corporation, F. Hoffmann-La Roche, LifeScan, Medtronic, Nova Biomedical and Trividia Health are some of the major industry participants providing advanced glucose self-monitoring devices.

Contact Us:

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone:1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Web: www.gminsights.com/

About Global Market Insights:

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

This release was published on openPR.